Drug Discovery

Landos Biopharma raises $10m in series A financing

Landos Biopharma, an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced that it has raised $10m in a series A financing led by life sciences investment management firm Perceptive Advisors, which will serve as its exclusive investor for the Series A round.

MilliporeSigma opens China’s first end-to-end biodevelopment center in Shanghai

MilliporeSigma announced the opening of its first BioReliance end-to-end biodevelopment center in the Asia Pacific (APAC) region.

GSK, AstraZeneca, Labcyte form alliance to develop acoustic mass spectrometry

Labcyte announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with Mass Spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications.

Ultragenyx proposes to acquire Dimension Therapeutics

Ultragenyx Pharmaceutical has made a proposal to acquire all of the outstanding shares of common stock of Dimension Therapeutics for $5.50 per share, or approximately $138m, in cash at close to be effectuated via a tender offer.

Mustang Bio announces expansion of CAR T pipeline into CD20-directed immunotherapies

Mustang Bio, a Fortress Biotech company, has announced the expansion of its pipeline of CAR T therapies into CD20-directed immunotherapies.

Inotek Pharmaceuticals announces merger deal with Rocket Pharmaceuticals

Inotek Pharmaceuticals announced that it has entered into a definitive merger agreement with US-based gene therapy company Rocket Pharmaceuticals.

Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI

Summit Therapeutics announces that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has awarded Summit a contract worth up to $62m.

Janssen scraps hepatitis C development program

Janssen Sciences Ireland UC has scrapped its ongoing hepatitis C development program citing the growing number of therapies available for treating the disease effectively.

Boehringer Ingelheim, Gubra to develop next generation obesity treatments

Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity.